You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:
17 Items
Cancer Type: Hematologic, Lymphoma - T-cell, Rare Diseases     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
... Show more tags
Quick Link(s):
Regimen Monograph
Sep 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate),
riTUXimab (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Dec 2017
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
... Show more tags
Quick Link(s):
Regimen Monograph
Nov 2019
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
... Show more tags
Drugs Used:
capecitabine,
temozolomide (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
mitoXANTRONE,
fludarabine,
cyclophosphamide,
alemtuzumab (Compassionate)
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Sarcoma, Ewing's     
Intent: Palliative
Drugs Used:
temozolomide (Unfunded),
irinotecan
... Show more tags
Quick Link(s):
Regimen Monograph
Oct 2017
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
Funding:
ODB - General Benefit
    niLUTAmide
... Show more tags
Drugs Used:
niLUTAmide
... Show more tags
Quick Link(s):
Regimen Monograph
Sep 2018
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
Exceptional Access Program
    pazopanib - For first-line treatment of advanced or metastatic renal cell carcinoma of clear cell histology in patients with good performance status (ECOG 0-1), with specific criteria
... Show more tags
Drugs Used:
pazopanib
... Show more tags
Quick Link(s):
Regimen Monograph
Aug 2019
Cancer Type: Sarcoma, Soft Tissue     
Intent: Palliative
Drugs Used:
pazopanib (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria
... Show more tags
Drugs Used:
ponatinib
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
... Show more tags
Drugs Used:
ponatinib
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Drugs Used:
temozolomide (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019